Thermo Fisher Scientific agreed to acquire Clario, a clinical‑trial data and endpoint technology firm, for about $8.8–$9 billion to expand its digital capabilities in clinical research. The purchase folds Clario into Thermo Fisher’s Laboratory Products and Biopharma Services segment and complements its PPD contract‑research assets. Thermo Fisher framed the deal as strategic, saying Clario’s software and data management tools will accelerate trial execution and endpoint analytics across its CRO and lab services businesses. Analysts note the acquisition strengthens Thermo Fisher’s vertical integration in late‑stage clinical development and could streamline sponsor workflows. The transaction underscores ongoing consolidation as large suppliers buy digital platforms to offer end‑to‑end trial services and respond to sponsors’ demand for faster, tech‑enabled trials.